InsiderSignalSign in

← Insider buys

LUNG

Pulmonx Corporation · Healthcare

Insiders sold $389K of Pulmonx Corporation in the last 12 months and bought none

$0Bought, 12 mo

$389KSold, 12 mo

$76.4MMarket cap

LUNG over the last year

No insider buys filed in this year

LUNG after insider buys

3 months after each buy, from the first price a copier could get.

1 buy has 3 months of prices so far. A record shows here at 3.

Every filing

74 insider filings since 2020, newest first

Glendon E. French III · President and CEO

$95K−3.5%Sep 3

Srikanth Radhakrishnan · Chief Science & Techn. Officer

$32K−4.3%Sep 3

David Aaron Lehman · General Counsel

$32K−3.8%Sep 3

Glendon E. French III · President and CEO

$87K−4.5%Jun 3

Glendon E. French III · President and CEO

$97K−3.0%Mar 4

Daniel P Florin · Director

$46K−20.0%Dec 9

Daniel P Florin · Director

$71K+25.0%Jun 5

Glendon E. French III · Director

$133K−2.0%Nov 26

Glendon E. French III · Director

$130K−2.0%Oct 21

Glendon E. French III · Director

$162K−2.0%Sep 18

Geoffrey Beran Rose · Chief Commercial Officer

$31K−2.0%Sep 5

David Aaron Lehman · General Counsel

$39K−3.0%Sep 5

David Aaron Lehman · General Counsel

$38K−3.0%Jun 5

Geoffrey Beran Rose · Chief Commercial Officer

$30K−1.0%Jun 5

Geoffrey Beran Rose · Chief Commercial Officer

$28K−1.0%Mar 5

David Aaron Lehman · General Counsel

$39K−2.0%Mar 5

Glendon E. French III · President and CEO

$63K−1.0%Mar 5

Glendon E. French III · President and CEO

$292K−2.0%Feb 16

Glendon E. French III · President and CEO

$128K−1.0%Jan 22

Glendon E. French III · President and CEO

$124K−1.0%Dec 22

Geoffrey Beran Rose · Chief Commercial Officer

$30K−1.0%Dec 5

David Aaron Lehman · General Counsel

$39K−2.0%Dec 5

Glendon E. French III · President and CEO

$69K−1.0%Dec 5

Derrick Sung · CFO

$42K−1.0%Sep 6

Geoffrey Beran Rose · Chief Commercial Officer

$28K−1.0%Sep 6

David Aaron Lehman · General Counsel

$38K−2.0%Sep 6

Glendon E. French III · President and CEO

$65K−1.0%Sep 6

Glendon E. French III · President and CEO

$190K−1.0%Jul 24

Glendon E. French III · President and CEO

$127K−1.0%Jun 20

Derrick Sung · CFO

$49K−1.0%Jun 2

Geoffrey Beran Rose · Chief Commercial Officer

$33K−1.0%Jun 2

David Aaron Lehman · General Counsel

$43K−2.0%Jun 2

Glendon E. French III · President and CEO

$75K−1.0%Jun 2

Glendon E. French III · President and CEO

Glendon E. French III · President and CEO

$500K−2.0%Sep 19

Glendon E. French III · President and CEO

Glendon E. French III · President and CEO

$1.0M−5.0%Aug 22

Glendon E. French III · President and CEO

Glendon E. French III · President and CEO

Glendon E. French III · President and CEO

$677K−2.0%Feb 22

Glendon E. French III · President and CEO

$628K−2.0%Jan 24

Glendon E. French III · President and CEO

$776K−2.0%Dec 17

Geoffrey Beran Rose · Chief Commercial Officer

$672K−15.0%Dec 16

Derrick Sung · CFO

$190K−3.0%Dec 16

Glendon E. French III · President and CEO

$1.1M−2.0%Dec 3

Glendon E. French III · President and CEO

$1.0M−2.0%Dec 3

Glendon E. French III · President and CEO

Glendon E. French III · President and CEO

$899K−2.0%Nov 22

Geoffrey Beran Rose · Chief Commercial Officer

$280K−5.0%Nov 16

Glendon E. French III · President and CEO

$994K−2.0%Oct 22

About Pulmonx Corporation

Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.